前臨床CRO市場：サービス、用途、エンドユーザー別-2025-2030年の世界予測

前臨床CRO市場は、2023年に62億5,000万米ドルと評価され、2024年には68億5,000万米ドルに達すると予測され、CAGR 9.68％で成長し、2030年には119億5,000万米ドルに達すると予測されています。

前臨床試験受託機関（CRO）は、ターゲット同定から前臨床試験まで幅広い研究サービスをアウトソーシングすることで、医薬品開発において重要な役割を果たしています。前臨床CROの範囲は、in vitroおよびin vivoモデル、薬物動態学、毒性学、生物学的分析試験など、幅広いサービスを網羅しています。製薬会社がコスト管理と複雑な規制状況を乗り切りながら医薬品開発プロセスの加速を目指す中、前臨床CROの必要性と応用はより顕著になっています。最終用途の範囲は、創薬とバリデーションのための専門家の指導と施設を求める製薬会社やバイオテクノロジー企業、学術研究機関、政府機関が主な対象です。

前臨床CROの市場成長は、研究開発投資の増加、創薬手法の技術的進歩、個別化医療に対する需要の高まりなどの要因によってもたらされます。前臨床試験にAIや機械学習を導入するなどの新たな機会は、業務の大幅な効率化と臨床結果の予測可能性の向上につながります。また、生物由来医薬品への関心が高まっていることから、生物製剤やバイオシミラーに関連するサービスの拡大も潜在的な成長分野です。しかし、市場競争、規制要件の進化、動物実験をめぐる倫理的懸念など、限界や課題にも直面しています。

技術革新の主要分野のひとつは、臓器オンチップ技術のような代替試験モデルの開発であり、これは医薬品試験のより倫理的で精密なアプローチを約束するものです。さらに、データ管理を改善し、CROとスポンサー間の連携を強化するためのデジタルプラットフォームのさらなる統合も、成長を促進する可能性があります。市場の性質はダイナミックで競争的であり、サービス・ポートフォリオと世界・リーチを強化するための戦略的提携、合併、買収に重点が置かれています。このような動きの中で成功するためには、CRO企業は柔軟でカスタマイズ可能なサービスを提供し、最先端技術に投資して顧客の進化するニーズに応えるとともに、規制の変化に先手を打つことに注力すべきです。

市場力学：急速に進化する前臨床CRO市場の主要市場インサイトを公開

前臨床CRO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬・バイオ医薬品企業による新薬・治療法開発のための研究開発活動の活発化
  • 製薬企業による医薬品開発業務のCROへのアウトソーシング動向の高まり
  • 個別化医薬品の開発への注目の高まり
• 市場抑制要因
  • 前臨床CROサービスに関連する高コストと時間のかかる制約
• 市場機会
  • より効率的で費用対効果の高い前臨床研究を可能にする技術の進歩の高まり
  • モノクローナル抗体、ワクチン、細胞療法を含む生物製剤の前臨床研究の高い可能性
• 市場の課題
  • 国際規制当局による厳しい規制とガイドライン

ポーターの5つの力：前臨床CRO市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：前臨床CRO市場における外部からの影響の把握

外部マクロ環境要因は、前臨床CRO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析前臨床CRO市場における競合情勢の把握

前臨床CRO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス前臨床CRO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、前臨床CRO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬企業やバイオ医薬品企業による新薬や治療法の開発に向けた研究開発活動の増加
    • 製薬企業による医薬品開発業務のCROへのアウトソーシング増加傾向
    • 個別化医療の開発への注目が高まる
  • 抑制要因
    • 前臨床CROサービスに関連する高コストと時間のかかる制約
  • 機会
    • より効率的で費用対効果の高い前調査を可能にする技術の進歩
    • モノクローナル抗体、ワクチン、細胞療法などの生物製剤の前調査の大きな可能性
  • 課題
    • 国際規制当局が定める厳格な規制とガイドライン
• 市場セグメンテーション分析
  • サービス：安全性と規制遵守の側面に重点を置いた毒性試験サービスの利用が急増
  • エンドユーザー：バイオ医薬品企業による前臨床CROの使用法の進化
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 前臨床CRO市場：サービス別

• バイオ分析とDMPK研究
• 毒性試験

第7章 前臨床CRO市場：用途別

• 心血管疾患
• 皮膚科
• 胃腸
• 泌尿器と女性の健康
• 血液学
• 免疫疾患
• 感染症
• 代謝障害
• 神経学
• 腫瘍学
• 眼科
• 呼吸器疾患

第8章 前臨床CRO市場：エンドユーザー別

• バイオ医薬品企業
• 政府機関および学術機関
• 医療機器企業

第9章 南北アメリカの前臨床CRO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の前臨床CRO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの前臨床CRO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • CRO企業TriApex、Legend Capital主導のシリーズC資金調達ラウンドを完了
  • PsychoGenicsが新薬発見のためのAI対応プラットフォームeCubeを発表
  • プロシア、医薬品の安全性に関する判断を迅速化するために前臨床研究開発を大幅に拡大すると発表
  • AmplifyBioが細胞療法の特性評価を拡大し、前臨床開発のギャップを埋める
  • Clinchoice、CRO買収により事業拡大を継続
  • QPS、台湾に新たな前調査施設を開設
  • CROアバニアがマクシスを買収
  • ApaxがPorsoltの過半数株式を取得し、同社の成長戦略をサポートし、前臨床サービスにおける世界的リーダーとなる
  • クライオポート、細胞・遺伝子治療の推進に向けシネオス・ヘルスとの戦略的提携を発表
  • クラウン・バイオサイエンスとERSジェノミクスがゲノム編集特許に関するCRISPR/Cas9の世界ライセンシング契約を発表
  • ドメイン・セラピューティクスとエクスプリサイトが免疫腫瘍学分野で提携契約を締結
  • セレリオン、初期段階の臨床薬理学ユニットを拡大
  • ClinChoice、シリーズEラウンドで1億5,000万米ドルを調達
  • ヘラ・バイオラボ、チャールズ・リバーとの独占的世界ライセンス契約を発表
  • IonsGate前臨床サービスとInSilicoTrialsが提携

企業一覧

• Phenos GmbH
• Syneos Health, Inc.
• Eurofins Scientific SE
• Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
• Parexel International Corporation.
• CTI Clinical Trial and Consulting, Inc.
• Shanghai Medicilon Inc.
• ICON PLC
• Atuka Inc.
• Gubra
• MCI Group Holding SA
• SGS SA
• Immusmol SAS
• PsychoGenics Inc.
• Laboratory Corporation of America Holding
• Hera Biolabs
• IQVIA Inc.
• Biotrofix, Inc.
• Medpace Holdings, Inc.
• Veristat, LLC
• Crown Bioscience, Inc.
• PharmaCircle LLC
• PPD by Thermo Fisher Scientific Inc.
• Sanofi S.A.
• Celerion
• BenchSci
• SCiAN Services Inc.
• Vimta Labs Limited
• Transpharmation
• Diag2Tec SAS
• MD Biosciences
• ImQuest BioSciences
• QPS Holdings, LLC
• Invivotek by Genesis Biotechnology Group, LLC
• Intertek Group PLC
• WuXi AppTec Co., Ltd.
• 10x Genomics, Inc.
• Novartis AG
• AmplifyBio
• Charles River Laboratories International, Inc.
• F. Hoffmann-La Roche Ltd.
• Inotiv, Inc.
• Bioserve Biotechnologies（India）PVT Ltd. by REPROCELL Inc.

LIST OF FIGURES

• FIGURE 1. PRECLINICAL CRO MARKET RESEARCH PROCESS
• FIGURE 2. PRECLINICAL CRO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PRECLINICAL CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRECLINICAL CRO MARKET DYNAMICS
• TABLE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOANALYSIS & DMPK STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRECLINICAL CRO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRECLINICAL CRO MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRECLINICAL CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRECLINICAL CRO MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRECLINICAL CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRECLINICAL CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRECLINICAL CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRECLINICAL CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GOVERNMENT & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 55. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 58. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. INDIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 110. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. ITALY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. POLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 122. POLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. POLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. QATAR PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 125. QATAR PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. QATAR PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 155. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

The Preclinical CRO Market was valued at USD 6.25 billion in 2023, expected to reach USD 6.85 billion in 2024, and is projected to grow at a CAGR of 9.68%, to USD 11.95 billion by 2030.

Preclinical Contract Research Organizations (CROs) play a crucial role in drug development by providing outsourced research services that range from target identification to preclinical testing. The scope of preclinical CROs encompasses a wide array of services, including in vitro and in vivo models, pharmacokinetics, toxicology, and bioanalytical testing. As pharmaceutical companies aim to accelerate their drug development processes while managing costs and navigating complex regulatory landscapes, the necessity and application of preclinical CROs have become more pronounced. The end-use scope predominantly covers pharmaceutical and biotechnology firms, academic research institutes, and government bodies seeking expert guidance and facilities for drug discovery and validation.

Market growth for preclinical CROs is driven by factors such as increasing R&D investments, technological advancements in drug discovery methods, and an escalating demand for personalized medicine. Emerging opportunities, such as the adoption of AI and machine learning in preclinical studies, present avenues for significant operational efficiencies and improved predictability of clinical outcomes. Another potential growth area lies in expanding services related to biologics and biosimilars, given the rising interest in biologically-derived drugs. However, the market also faces limitations and challenges, including high competition, evolving regulatory requirements, and ethical concerns around animal testing.

One major area of innovation lies in the development of alternative testing models like organ-on-chip technologies, which promise a more ethical and precise approach to drug testing. Additionally, further integration of digital platforms to improve data management and increase collaboration between CROs and sponsors can also propel growth. The nature of the market is dynamic and competitive, with an increased focus on strategic partnerships, mergers, and acquisitions to enhance service portfolios and global reach. To thrive amidst these dynamics, CRO businesses should focus on offering flexible, customizable services and investing in cutting-edge technologies to meet the evolving needs of their clientele while staying ahead of regulatory changes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preclinical CRO Market

The Preclinical CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
  • Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
  • Growing focus on the development of personalized medicines
• Market Restraints
  • High cost and time-consuming constraints associated with preclinical CRO services
• Market Opportunities
  • Growing advances in technologies to enable more efficient and cost-effective preclinical research
  • High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
• Market Challenges
  • Stringent regulations and guidelines set by international regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Preclinical CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preclinical CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preclinical CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preclinical CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preclinical CRO Market

A detailed market share analysis in the Preclinical CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preclinical CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preclinical CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preclinical CRO Market, highlighting leading vendors and their innovative profiles. These include Phenos GmbH, Syneos Health, Inc., Eurofins Scientific SE, Jubilant Biosys Ltd. byJubilant Pharmova Limited Company, Parexel International Corporation., CTI Clinical Trial and Consulting, Inc., Shanghai Medicilon Inc., ICON PLC, Atuka Inc., Gubra, MCI Group Holding SA, SGS SA, Immusmol SAS, PsychoGenics Inc., Laboratory Corporation of America Holding, Hera Biolabs, IQVIA Inc., Biotrofix, Inc., Medpace Holdings, Inc., Veristat, LLC, Crown Bioscience, Inc., PharmaCircle LLC, PPD by Thermo Fisher Scientific Inc., Sanofi S.A., Celerion, BenchSci, SCiAN Services Inc., Vimta Labs Limited, Transpharmation, Diag2Tec SAS, MD Biosciences, ImQuest BioSciences, QPS Holdings, LLC, Invivotek by Genesis Biotechnology Group, LLC, Intertek Group PLC, WuXi AppTec Co., Ltd., 10x Genomics, Inc., Novartis AG, AmplifyBio, Charles River Laboratories International, Inc., F. Hoffmann-La Roche Ltd., Inotiv, Inc., and Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc..

Market Segmentation & Coverage

This research report categorizes the Preclinical CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Services, market is studied across Bioanalysis & DMPK Studies and Toxicology Testing.
• Based on Application, market is studied across Cardiovascular Disease, Dermatology, Gastrointestinal, Genitourinary & Women's Health, Hematology, Immunological Disorders, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
• Based on End-User, market is studied across Biopharmaceutical Companies, Government & Academic Institutes, and Medical Device Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
    • 5.1.1.2. Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
    • 5.1.1.3. Growing focus on the development of personalized medicines
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and time-consuming constraints associated with preclinical CRO services
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing advances in technologies to enable more efficient and cost-effective preclinical research
    • 5.1.3.2. High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and guidelines set by international regulatory authorities
• 5.2. Market Segmentation Analysis
  • 5.2.1. Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects
  • 5.2.2. End-User: Evolving usage of preclinical CRO by biopharmaceutical companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Preclinical CRO Market, by Services

• 6.1. Introduction
• 6.2. Bioanalysis & DMPK Studies
• 6.3. Toxicology Testing

7. Preclinical CRO Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular Disease
• 7.3. Dermatology
• 7.4. Gastrointestinal
• 7.5. Genitourinary & Women's Health
• 7.6. Hematology
• 7.7. Immunological Disorders
• 7.8. Infectious Diseases
• 7.9. Metabolic Disorders
• 7.10. Neurology
• 7.11. Oncology
• 7.12. Ophthalmology
• 7.13. Respiratory Disorders

8. Preclinical CRO Market, by End-User

• 8.1. Introduction
• 8.2. Biopharmaceutical Companies
• 8.3. Government & Academic Institutes
• 8.4. Medical Device Companies

9. Americas Preclinical CRO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Preclinical CRO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Preclinical CRO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
  • 12.3.2. PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
  • 12.3.3. Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
  • 12.3.4. AmplifyBio Expands Cell Therapy Characterization, Fills Gap in Preclinical Development
  • 12.3.5. Clinchoice Continues Expansion with CRO Acquisition
  • 12.3.6. QPS opens an additional preclinical research facility in Taiwan
  • 12.3.7. CRO Avania Acquires MAXIS
  • 12.3.8. Apax Acquires a Majority Stake in Porsolt to Support its Growth Strategy and Become a Global Leader in Preclinical Services
  • 12.3.9. Cryoport Announces Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
  • 12.3.10. Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
  • 12.3.11. Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
  • 12.3.12. Celerion Expands Early Phase Clinical Pharmacology Units
  • 12.3.13. ClinChoice Raises USD 150 Million in Series E Round
  • 12.3.14. Hera BioLabs Announces Exclusive Global License With Charles River
  • 12.3.15. IonsGate Preclinical Services and InSilicoTrials Form Partnership

Companies Mentioned

• 1. Phenos GmbH
• 2. Syneos Health, Inc.
• 3. Eurofins Scientific SE
• 4. Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
• 5. Parexel International Corporation.
• 6. CTI Clinical Trial and Consulting, Inc.
• 7. Shanghai Medicilon Inc.
• 8. ICON PLC
• 9. Atuka Inc.
• 10. Gubra
• 11. MCI Group Holding SA
• 12. SGS SA
• 13. Immusmol SAS
• 14. PsychoGenics Inc.
• 15. Laboratory Corporation of America Holding
• 16. Hera Biolabs
• 17. IQVIA Inc.
• 18. Biotrofix, Inc.
• 19. Medpace Holdings, Inc.
• 20. Veristat, LLC
• 21. Crown Bioscience, Inc.
• 22. PharmaCircle LLC
• 23. PPD by Thermo Fisher Scientific Inc.
• 24. Sanofi S.A.
• 25. Celerion
• 26. BenchSci
• 27. SCiAN Services Inc.
• 28. Vimta Labs Limited
• 29. Transpharmation
• 30. Diag2Tec SAS
• 31. MD Biosciences
• 32. ImQuest BioSciences
• 33. QPS Holdings, LLC
• 34. Invivotek by Genesis Biotechnology Group, LLC
• 35. Intertek Group PLC
• 36. WuXi AppTec Co., Ltd.
• 37. 10x Genomics, Inc.
• 38. Novartis AG
• 39. AmplifyBio
• 40. Charles River Laboratories International, Inc.
• 41. F. Hoffmann-La Roche Ltd.
• 42. Inotiv, Inc.
• 43. Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc.